BRAF V600E and MAP2K1 Mutations in Hairy Cell Leukemia and Splenic Marginal Zone Lymphoma Cases

Sang-Yong SHIN; Seung-Tae LEE; Hee-Jin KIM; Chang-Seok KI; Chul-Won JUNG; Jong-Won KIM; Sun-Hee KIM.
Annals of Laboratory Medicine ; : 257-259, 2015.
Artículo en Inglés | WPRIM | ID: wpr-29319

Documentos relacionados

  1. Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray.
  2. Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana Linfomi.
  3. Successful Treatment of Large B-Cell Lymphoma in a Child with Compound Heterozygous Mutation in the <i>ATM</i> Gene.
  4. The Impact of Drug Metabolism Gene Polymorphisms on Therapeutic Response and Survival in Diffuse Large B-Cell Lymphoma Patients.
  5. Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial.
  6. High expression of AP2M1 correlates with worse prognosis by regulating immune microenvironment and drug resistance to R-CHOP in diffuse large B cell lymphoma.
  7. Single-Center Analysis of Characteristics and Outcomes of De Novo, Concurrent, and Transformed Diffuse Large B-Cell Lymphoma.
  8. Long-term follow-up after R-High CHOP/CHASER/LEED with Auto-PBSCT in untreated mantle cell lymphoma-Final analysis of JCOG0406.
  9. Current Frontline Treatment of Diffuse Large B-Cell Lymphoma.
  10. New standards of care for treatment of diffuse large B-cell lymphoma.